Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such antipsychotics in schizophrenia, mania, and bipolar depression based on the results of several phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further - not just within, but beyond the scope of clinical trials, as well as to increase the understanding of the role of D3-D2 partial agonism both theoretically and from experience in overlapping psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, mania or even major depression.
The aim of this Research Topic is to examine the role of dopamine partial agonists, in the treatment of overlapping psychiatric disorders within and beyond clinical trials. Moving from previous treatment aims such as response and remission to recovery, the ultimate goal of modern psychiatry is to provide the right treatment to the patient at the right time. Given the fact that many of the major psychiatric disorders have shared genetic, neural as well as symptomatic elements, there is a high probability that there are common medical solutions too. Based on the results of several phase II and III clinical trials that have shown efficacy in schizophrenia, mania, and bipolar depression, there is a high possibility that dopamine partial agonists, such as cariprazine can be safe and efficacious in other psychiatric disorders as well.
This Research Topic welcomes any type of manuscripts from Reviews, Systematic Reviews and meta-analyses, Case Reports, Hypothesis and Theory and Opinion articles to Original Research in the following topics:
• Shared characteristics of major psychiatric disorders from genetics to symptoms
• The role of dopamine partial agonists in the treatment of overlapping psychiatric disorders – in general, or with a special focus on cariprazine
• Efficacy and effectiveness of novel antipsychotic medications such as cariprazine within and beyond clinical trials i.e. post-hoc analyses, original research, case reports, real-life data
• Safety and tolerability of cariprazine within and beyond clinical trials i.e. post-hoc analyses, original research, case reports, real-life data
• Novel diagnostic and treatment approaches in major psychiatric disorders – from discrete categories to spectrums
Dr. György Németh is an employee of Gedeon Richter Plc. The other Topic Editors declare no competing interests with regard to the Research Topic subject. We would like to acknowledge that Dr. Agota Barabássy has acted as coordinator and has contributed to the preparation of the proposal for this Research Topic.
Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such antipsychotics in schizophrenia, mania, and bipolar depression based on the results of several phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further - not just within, but beyond the scope of clinical trials, as well as to increase the understanding of the role of D3-D2 partial agonism both theoretically and from experience in overlapping psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, mania or even major depression.
The aim of this Research Topic is to examine the role of dopamine partial agonists, in the treatment of overlapping psychiatric disorders within and beyond clinical trials. Moving from previous treatment aims such as response and remission to recovery, the ultimate goal of modern psychiatry is to provide the right treatment to the patient at the right time. Given the fact that many of the major psychiatric disorders have shared genetic, neural as well as symptomatic elements, there is a high probability that there are common medical solutions too. Based on the results of several phase II and III clinical trials that have shown efficacy in schizophrenia, mania, and bipolar depression, there is a high possibility that dopamine partial agonists, such as cariprazine can be safe and efficacious in other psychiatric disorders as well.
This Research Topic welcomes any type of manuscripts from Reviews, Systematic Reviews and meta-analyses, Case Reports, Hypothesis and Theory and Opinion articles to Original Research in the following topics:
• Shared characteristics of major psychiatric disorders from genetics to symptoms
• The role of dopamine partial agonists in the treatment of overlapping psychiatric disorders – in general, or with a special focus on cariprazine
• Efficacy and effectiveness of novel antipsychotic medications such as cariprazine within and beyond clinical trials i.e. post-hoc analyses, original research, case reports, real-life data
• Safety and tolerability of cariprazine within and beyond clinical trials i.e. post-hoc analyses, original research, case reports, real-life data
• Novel diagnostic and treatment approaches in major psychiatric disorders – from discrete categories to spectrums
Dr. György Németh is an employee of Gedeon Richter Plc. The other Topic Editors declare no competing interests with regard to the Research Topic subject. We would like to acknowledge that Dr. Agota Barabássy has acted as coordinator and has contributed to the preparation of the proposal for this Research Topic.
